THE INTERLEUKIN-2 RECEPTOR DOWN-REGULATES THE EXPRESSION OF CYTOCHROME-P450 IN CULTURED RAT HEPATOCYTES

被引:43
作者
TINEL, M
ROBIN, MA
DOOSTZADEH, J
MARATRAT, M
BALLET, F
FARDEL, N
ELKAHWAJI, J
BEAUNE, P
DAUJAT, M
LABBE, G
PESSAYRE, D
机构
[1] HOP BEAUJON, INSERM, U24, F-92118 CLICHY, FRANCE
[2] RHONE POULENC RORER SA, DEPT SECUR MEDICAMENT, ALFORDVILLE, FRANCE
[3] ROUSSEL UCLAF, MOLEC TOXICOL LAB, ROMAINVILLE, FRANCE
[4] FAC NECKER ENFANTS MALAD, INSERM, U75, PARIS, FRANCE
[5] INSERM, U128, MONTPELLIER, FRANCE
关键词
D O I
10.1016/0016-5085(95)90648-7
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background & Aims: Interleukin (IL) 2 is used in advanced cancers, but its effects on cytochrome P450 remain unknown. Other cytokines down-regulate hepatic cytochrome P450, but it is not known whether this involves cytokine receptors. The aim of this study was to determine whether the IL-2 receptor is expressed on hepatocytes and whether its activation by IL-2 depresses cytochrome P450 in cultured rat hepatocytes. Methods: A monoclonal antibody specific for the rat IL-2 receptor alpha chain was used to label the receptor, whereas effects on cytochrome P450 were determined after 24 hours of culture with human recombinant IL-2 (5000 U/mL). Results: The presence of the IL-2 receptor in hepatocytes was shown by immunoblots, flow cytometry, and scanning confocal microscopy. IL-2 caused a 46% decrease in total cytochrome P450; a 35%, 35%, 36%, 26%, and 56% decrease in immunoreactive cytochrome P4501A1, 2B, 2C11, 2D1, and 3A, respectively; and a marked decrease in cytochrome P4503A2 and 2C11 messenger RNAs. Addition to the culture medium of the anti-receptor antibody or the tyrosine kinase inhibitor genistein prevented the IL-2-mediated decrease in cytochrome P450. Conclusions: IL-2 down-regulates the expression of cytochrome P450 genes in cultured rat hepatocytes by interacting with its receptor expressed on hepatocytes.
引用
收藏
页码:1589 / 1599
页数:11
相关论文
共 59 条
[1]  
ABDELRAZZAK Z, 1993, MOL PHARMACOL, V44, P707
[2]   OXIDANTS, ANTIOXIDANTS, AND THE DEGENERATIVE DISEASES OF AGING [J].
AMES, BN ;
SHIGENAGA, MK ;
HAGEN, TM .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1993, 90 (17) :7915-7922
[3]  
BARCLAY AN, 1981, IMMUNOLOGY, V42, P593
[4]  
BARKER CW, 1992, J BIOL CHEM, V267, P8050
[5]   MONOCLONAL-ANTIBODIES AGAINST HUMAN-LIVER CYTOCHROME-P-450 [J].
BEAUNE, P ;
KREMERS, P ;
LETAWEGOUJON, F ;
GIELEN, JE .
BIOCHEMICAL PHARMACOLOGY, 1985, 34 (19) :3547-3552
[6]  
Borenfreud E, 1984, METHODS CELL SCI, V9, P7, DOI DOI 10.1007/BF01666038
[7]  
BURKE MD, 1977, DRUG METAB DISPOS, V5, P1
[8]   FUNCTIONAL INTERLEUKIN-2 RECEPTORS ON INTESTINAL EPITHELIAL-CELLS [J].
CIACCI, C ;
MAHIDA, YR ;
DIGNASS, A ;
KOIZUMI, M ;
PODOLSKY, DK .
JOURNAL OF CLINICAL INVESTIGATION, 1993, 92 (01) :527-532
[9]   INTERFERON SUPPRESSES ERYTHROMYCIN METABOLISM IN RATS AND HUMAN-SUBJECTS [J].
CRAIG, PI ;
TAPNER, M ;
FARRELL, GC .
HEPATOLOGY, 1993, 17 (02) :230-235
[10]  
CRAIG PI, 1990, MOL PHARMACOL, V38, P313